Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies.
Benedito Arruda CarneiroLudimila CavalcanteDevalingam MahalingamAnwaar SaeedHoward SafranWen Wee MaAndrew L CovelerSteven Francis PowellBruno R BastosElizabeth J DavisVaibhav SahaiWilliam MikrutJames LongstrethSheri SmithTaylor M WeiskittelHu LiBrittany A BordenRobert Donald HarveySolmaz SahebjamAndres CervantesAustin KoukolAndrew P MazarNeeltje SteeghsRazelle KurzrockFrancis J GilesPamela N MunsterPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Elraglusib had a favorable toxicity profile as monotherapy and combined with chemotherapy and was associated with clinical benefit supporting further clinical evaluation in combination with chemotherapy.